Keywords
How to Cite
Abstract
Ushbu maqolada miasteniya kasalligini immunologik va patogenetik asosda davolashning zamonaviy usullari yoritilgan. Miasteniya — bu autoimmun xususiyatga ega bo‘lgan, asab-mushak uzatish mexanizmining buzilishi bilan kechuvchi surunkali kasallik bo‘lib, bemorlarda mushak zaifligi va charchoqlik bilan namoyon bo‘ladi. Tadqiqotda miasteniyaning immun tizimi bilan bog‘liq rivojlanish sabablari tahlil qilinadi va patogenetik jihatdan asoslangan davolash strategiyalariga to‘xtalinadi. Xususan, immunosupressiv vositalar, plazmaferez, yuqori dozali immunoglobulinlar, shuningdek, yangi biologik dori vositalarining samaradorligi muhokama qilinadi. Maqolada shuningdek davolashda individual yondashuv va bemor holatiga mos ravishda terapiya tanlash zarurligi alohida ta’kidlanadi.
References
1. Gilhus N.E., Tzartos S., Evoli A. et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
2. Drachman D.B. Myasthenia gravis. N Engl J Med. 1994;330(25):1797–1810.
3. Sanders D.B., Wolfe G.I., Benatar M. et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419–425.
4. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357(9274):2122–2128.
5. Narayanaswami P., Sanders D.B., Wolfe G.I. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–122.
This work is licensed under a Creative Commons Attribution 4.0 International License.
